Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | TLR2 | O60603 | 6/20 | 0.46 |
| ▸ | TLR1 | Q15399 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | GLP1R | P43220 | 5/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.37 |
| ▸ | KLK7 | P49862 | 1/20 | 0.37 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20450542 | 1.00 | KMT2A (0.49) | KMT2ATLR2TLR1MEN1ALDH1A1 | |
| SCHEMBL29617449 | 1.00 | KMT2A (0.49) | KMT2ATLR2TLR1MEN1ALDH1A1 | |
| SCHEMBL20450572 | 1.00 | KMT2A (0.49) | KMT2ATLR2TLR1MEN1ALDH1A1 | |
| SCHEMBL20450541 | 1.00 | KMT2A (0.49) | KMT2ATLR2TLR1MEN1ALDH1A1 | |
| SCHEMBL20450574 | 1.00 | KMT2A (0.49) | KMT2ATLR2TLR1MEN1ALDH1A1 | |
| SCHEMBL20450603 | 0.94 | KMT2A (0.57) | KMT2ATLR2TLR1MEN1ALDH1A1 | |
| SCHEMBL20450573 | 0.94 | KMT2A (0.57) | KMT2ATLR2TLR1MEN1ALDH1A1 | |
| SCHEMBL20450575 | 0.94 | KMT2A (0.57) | KMT2ATLR2TLR1MEN1ALDH1A1 | |
| SCHEMBL20450605 | 0.94 | KMT2A (0.57) | KMT2ATLR2TLR1MEN1ALDH1A1 | |
| SCHEMBL23014554 | 0.89 | TLR2 (0.50) | KMT2ATLR2TLR1GLP1RMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12097241-B2 | Methods of treating kidney failure, and/or improving or stablizing renal function using modified relaxin polypeptides | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-09-24 | — | — | US | disclosed |
| US-12097242-B2 | Treatment of fibrosis, cardiovascular disease and heart failure with modified relaxin polypeptides | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-09-24 | — | — | US | disclosed |
| EP-3580232-B1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2023-09-20 | — | — | EP | disclosed |
| US-20220331402-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2022-10-20 | — | — | US | disclosed |
| US-20220211812-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2022-07-07 | — | — | US | disclosed |
| US-11364281-B2 | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and pharmaceutical compositions thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12097241-B2 | Methods of treating kidney failure, and/or improving or stablizing renal function using modified relaxin polypeptides | RXFP2, RXFP1, RXFP4 | KMT2A 3362/4885TLR2 2117/4885TLR1 2899/4885 |
| US-20220331402-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | RXFP2, RXFP1, RXFP4 | KMT2A 2670/4885TLR2 1114/4885TLR1 1483/4885 |
| US-11364281-B2 | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and pharmaceutical compositions thereof | RXFP2, RXFP1, RXFP4 | KMT2A 2556/4885TLR2 1015/4885TLR1 1451/4885 |
| US-20220211812-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | RXFP2, RXFP1, RXFP4 | KMT2A 2670/4885TLR2 1114/4885TLR1 1483/4885 |
| US-12097242-B2 | Treatment of fibrosis, cardiovascular disease and heart failure with modified relaxin polypeptides | RXFP2, RXFP1, RXFP4 | KMT2A 1915/4885TLR2 1110/4885TLR1 1437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.